SLC17A3

Across TCGA pan-cancer cohorts, SLC17A3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SLC17A3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC17A3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC17A3 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, KICH, and LUSC are the cancer types where SLC17A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC17A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+2.820	<.001	10	view →
KICH	Female	II,III,IV	−3.951	<.001	9	view →
LUSC	All	II,III,IV	−0.246	<.001	8	view →
LUAD	Female	II,III,IV	−0.172	<.001	6	view →
COAD	Female	III,IV	−0.062	<.001	5	view →
UCEC	All	All	−0.141	.001	4	view →
BLCA	All	All	−0.021	.009	4	view →
LIHC	Female	All	−1.224	<.001	3	view →
READ	Male	All	−0.040	.025	3	view →
CHOL	Male	All	−2.173	.004	2	view →
PAAD	Male	All	−0.065	.005	2	view →
PRAD	All	All	−0.040	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SLC17A3–KIRC

Open the KIRC breakdown →